Apogee Therapeutics Newsroom

Apogee Therapeutics Analyst Ratings

BenzingaDec 12 10:44 ET

TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating

Moomoo NewsDec 5 10:33 ET

Promising Potential of Apogee Therapeutics: A Buy Rating Backed by Innovative Pipeline and Strategic Approach

TipRanksDec 5 10:29 ET

TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)

TipRanksDec 5 10:19 ET

Apogee Therapeutics Price Target Raised to $110.00/Share From $95.00 by Guggenheim

Dow JonesDec 3 11:42 ET

Apogee Therapeutics Analyst Ratings

BenzingaDec 3 11:33 ET

CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89

Moomoo NewsDec 3 07:33 ET

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)

TipRanksDec 3 07:03 ET

Apogee Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesDec 2 10:47 ET

Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110

Moomoo NewsNov 27 07:33 ET

CCORF Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $89

Moomoo NewsNov 25 06:33 ET

Apogee Therapeutics Initiated at Buy by Canaccord Genuity

Dow JonesNov 25 06:32 ET

Apogee Therapeutics Analyst Ratings

BenzingaNov 25 06:22 ET

Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89

BenzingaNov 25 06:22 ET

BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100

Moomoo NewsNov 13 06:31 ET

TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating

Moomoo NewsNov 12 14:31 ET

BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100

Moomoo NewsOct 29 06:31 ET

TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating

Moomoo NewsOct 28 08:35 ET

Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush

Dow JonesOct 25 11:19 ET

Apogee Therapeutics Analyst Ratings

BenzingaOct 25 11:09 ET